
|Videos|May 15, 2017
Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer
Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
4
How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most
5










































